Imax Corp

IMAX remains in a Stage 2 advancing regime, trading above rising EMAs and SMAs. Price has consolidated sideways, holding near the mid-range of its recent advance and above the 50-day SMA. Short-term momentum is neutral with no clear timing edge, while medium-term bias stays bullish. The preferred approach is to stalk pullbacks into the rising EMA cluster around the 50-day SMA for an actionable entry.

• ↑FY25 revenue rose 40% YoY to $1.28B; adjusted EBITDA margin reached 45%.
• ↑The Odyssey opening weekend delivered $52M with 75% theater occupancy domestically.
• ↓Blockbuster dependence poses downside if major releases underperform.